Home
ZVSA
ZVSA News

Latest ZyVersa Therapeutics Inc. (ZVSA) News on July 27, 2024

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

GlobeNewswire

2 days ago

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

GlobeNewswire

8 days ago

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

GlobeNewswire

18 days ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

GlobeNewswire

2 months ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

GlobeNewswire

2 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

GlobeNewswire

3 months ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

GlobeNewswire

4 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

4 months ago

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

GlobeNewswire

4 months ago

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

GlobeNewswire

4 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

GlobeNewswire

5 months ago

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

GlobeNewswire

5 months ago

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

GlobeNewswire

5 months ago

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

GlobeNewswire

5 months ago

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

GlobeNewswire

6 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

IF Bancorp (NASDAQ:IROQ) investors are sitting on a loss of 10% if they invested five years ago

Simply Wall St.

6 months ago

IF Bancorp (NASDAQ:IROQ) investors are sitting on a loss of 10% if they invested five years ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

GlobeNewswire

6 months ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

GlobeNewswire

6 months ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

Business Wire

6 months ago

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

GlobeNewswire

6 months ago

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

GlobeNewswire

6 months ago

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

6 months ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

GlobeNewswire

6 months ago

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Ikena Oncology to lay off 35% of staff

BioPharma Dive

6 months ago

Ikena Oncology to lay off 35% of staff

Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

PR Newswire

6 months ago

Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

Benzinga

6 months ago

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

Signing Day Sports President Richard Symington Interviewed on “The Big Biz Show”

GlobeNewswire

6 months ago

Signing Day Sports President Richard Symington Interviewed on “The Big Biz Show”

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

ACCESSWIRE

6 months ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

China Liberal Education Holdings Limited Announces Share Consolidation

PR Newswire

6 months ago

China Liberal Education Holdings Limited Announces Share Consolidation

Cohen & Company Capital Markets Highlights Strong 2023

PR Newswire

6 months ago

Cohen & Company Capital Markets Highlights Strong 2023

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

GlobeNewswire

6 months ago

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

GlobeNewswire

6 months ago

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

GlobeNewswire

6 months ago

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Business Wire

6 months ago

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access

GlobeNewswire

7 months ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access

HNR Acquisition Corp Announces 2024 Operational Plan - Increase in Production Expected in 2024; Cost Control and Optimizing Production to Increase Revenues and Earnings

ACCESSWIRE

7 months ago

HNR Acquisition Corp Announces 2024 Operational Plan - Increase in Production Expected in 2024; Cost Control and Optimizing Production to Increase Revenues and Earnings

ACCESSWIRE

7 months ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

GlobeNewswire

7 months ago

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

GlobeNewswire

7 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

Yunji Announces Appointment of New Independent Director

PR Newswire

7 months ago

Yunji Announces Appointment of New Independent Director

Paragon Reminds OPT Shareholders to ONLY Vote Blue Proxy and Send Message to OPT Board that Change is Needed to Avoid Continued Shareholder Losses

ACCESSWIRE

7 months ago

Paragon Reminds OPT Shareholders to ONLY Vote Blue Proxy and Send Message to OPT Board that Change is Needed to Avoid Continued Shareholder Losses

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million

Business Wire

7 months ago

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

ACCESSWIRE

7 months ago

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

cbdMD Reduces Year over Year Net Loss from Operations by $55.8 Million

Newsfile

7 months ago

cbdMD Reduces Year over Year Net Loss from Operations by $55.8 Million

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

Zacks

7 months ago

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

Gaucho Holdings Announces Fireside Chat with CNBC and Fox Business Network Market Analyst Kenny Polcari

ACCESSWIRE

7 months ago

Gaucho Holdings Announces Fireside Chat with CNBC and Fox Business Network Market Analyst Kenny Polcari

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”

GlobeNewswire

7 months ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”

Dragonfly Energy Partners with Connexa, Fueling Industrial Solar Power System Applications

GlobeNewswire

7 months ago

Dragonfly Energy Partners with Connexa, Fueling Industrial Solar Power System Applications

Nuvve Releases Letter to Stockholders

PR Newswire

7 months ago

Nuvve Releases Letter to Stockholders

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

GlobeNewswire

7 months ago

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Chanson International Holding's (NASDAQ:CHSN) CEO Gang Li is the most upbeat insider, and their holdings increased by 238% last week

Simply Wall St.

8 months ago

Chanson International Holding's (NASDAQ:CHSN) CEO Gang Li is the most upbeat insider, and their holdings increased by 238% last week

Usio Welcomes Payments Veteran Mr. Jerry Uffner as Senior Vice President of Card Issuing Sales

Business Wire

8 months ago

Usio Welcomes Payments Veteran Mr. Jerry Uffner as Senior Vice President of Card Issuing Sales

EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody

Benzinga

8 months ago

EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody

La Rosa Implements Final Offer to Deliver Transparency in Real Estate Transactions

GlobeNewswire

8 months ago

La Rosa Implements Final Offer to Deliver Transparency in Real Estate Transactions

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

8 months ago

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

8 months ago

Carbon Revolution plc Awarded Program by Premium Brand of Major German Automaker

Globus Maritime (NASDAQ:GLBS) shareholders notch a 109% return over 1 year, yet earnings have been shrinking

Simply Wall St.

8 months ago

Globus Maritime (NASDAQ:GLBS) shareholders notch a 109% return over 1 year, yet earnings have been shrinking

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

GlobeNewswire

8 months ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Simply Wall St.

8 months ago

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

ACCESSWIRE

8 months ago

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

Valens Semiconductor's New USB3.2 Extension Solution Named as CES 2024 Innovation Awards Honoree

PR Newswire

8 months ago

Valens Semiconductor's New USB3.2 Extension Solution Named as CES 2024 Innovation Awards Honoree

Associated Press Finance

8 months ago

Gulf Resources: Q3 Earnings Snapshot

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

GlobeNewswire

8 months ago

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

GlobeNewswire

8 months ago

MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

PR Newswire

8 months ago

RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES QUARTERLY DIVIDEND

Investors Holding Back On CaliberCos Inc. (NASDAQ:CWD)

Simply Wall St.

8 months ago

Investors Holding Back On CaliberCos Inc. (NASDAQ:CWD)

Associated Press Finance

8 months ago

Phoenix New Media: Q3 Earnings Snapshot

GlobeNewswire

8 months ago

Interactive Strength Inc. d/b/a FORME Reports Third Quarter 2023 Results

Sonder Holdings Inc. Announces Third Quarter 2023 Financial Results

GlobeNewswire

8 months ago

Sonder Holdings Inc. Announces Third Quarter 2023 Financial Results

Strawberry Fields REIT Inc. Announces Share Repurchase Program

ACCESSWIRE

8 months ago

Strawberry Fields REIT Inc. Announces Share Repurchase Program

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire

8 months ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire

8 months ago

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

ACCESSWIRE

8 months ago

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

CHARLES & COLVARD REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

PR Newswire

9 months ago

CHARLES & COLVARD REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

Adamas One Corp. Announces Formation of Adamas Technologies

PR Newswire

9 months ago

Adamas One Corp. Announces Formation of Adamas Technologies

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire

9 months ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Cutera Provides Third Quarter 2023 Business Update

Business Wire

9 months ago

Cutera Provides Third Quarter 2023 Business Update

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire

9 months ago

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2023 Financial Results on November 14, 2023

Smith Micro Announces New Enhanced Solutions to SafePath® Platform for 2024

Business Wire

9 months ago

Smith Micro Announces New Enhanced Solutions to SafePath® Platform for 2024

Forza X1, Inc. (NASDAQ:FRZA) Q3 2023 Earnings Call Transcript

Insider Monkey

9 months ago

Forza X1, Inc. (NASDAQ:FRZA) Q3 2023 Earnings Call Transcript

CURO Group Holdings Corp. (NYSE:CURO) Q3 2023 Earnings Call Transcript

Insider Monkey

9 months ago

CURO Group Holdings Corp. (NYSE:CURO) Q3 2023 Earnings Call Transcript

BowFlex Inc. to Announce Fiscal Second Quarter 2024 Results on Tuesday, November 14, 2023

Business Wire

9 months ago

BowFlex Inc. to Announce Fiscal Second Quarter 2024 Results on Tuesday, November 14, 2023

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

GlobeNewswire

9 months ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Associated Press Finance

9 months ago

Teekay: Q3 Earnings Snapshot

Teekay Corporation Reports Third Quarter 2023 Results

GlobeNewswire

9 months ago

Teekay Corporation Reports Third Quarter 2023 Results

GT Biopharma Reports Third Quarter 2023 Financial Results

GlobeNewswire

9 months ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Share on Social Networks: